gms | German Medical Science

61st Annual Meeting of the German Society of Neurosurgery (DGNC) as part of the Neurowoche 2010
Joint Meeting with the Brazilian Society of Neurosurgery on the 20 September 2010

German Society of Neurosurgery (DGNC)

21 - 25 September 2010, Mannheim

Cerebral interstitial matrix metalloproteinase-9 (MMP-9) in patients following subarachnoid hemorrhage (SAH)

Meeting Abstract

  • Asita Sarrafzadeh - Division of Neurosurgery, Geneva University Hospitals, Geneva Neuroscience Center, Switzerland
  • Jean-Christophe Copin - Division of Intensive Care, Geneva University Hospitals, Geneva Neuroscience Center, Switzerland
  • Karl Schaller - Division of Neurosurgery, Geneva University Hospitals, Geneva Neuroscience Center, Switzerland
  • Philippe Bijlenga - Division of Neurosurgery, Geneva University Hospitals, Geneva Neuroscience Center, Switzerland
  • Peter Vajkoczy - Department of Neurosurgery, Charité, Universitätsmedizin Berlin
  • Yvan Gasche - Division of Intensive Care, Geneva University Hospitals, Geneva Neuroscience Center, Switzerland

Deutsche Gesellschaft für Neurochirurgie. 61. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC) im Rahmen der Neurowoche 2010. Mannheim, 21.-25.09.2010. Düsseldorf: German Medical Science GMS Publishing House; 2010. DocP1833

DOI: 10.3205/10dgnc304, URN: urn:nbn:de:0183-10dgnc3044

Published: September 16, 2010

© 2010 Sarrafzadeh et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Objective: MMP-9 is involved in the pathophysiology of ischemic stroke and might play a role in delayed ischemic injury due to vasospasm in SAH patients. The aim of this pilot study, was to determine de value of brain MMP-9 in SAH patients.

Methods: Bedside microdialysis was performed in 11 SAH patients (2F/9M, 51±10 years, WFNS Grade: 2–5). Probes were placed intraoperatively in brain areas at risk for delayed cerebral ischemia. MMP-9 was measured by zymographic analysis on microdialysates obtained at the day of bleeding (D0) and daily until day seven after SAH.

Results: Mean brain MMP-9 values at day 0 were 0.02 (range: 0–0.07) pg/ml in low grade (WFNS 2; n=4) versus 4.2 (range: 0.09–17.3) pg/ml in high grade patients (WFNS 4-5; n=7). In patients developing clinically symptomatic vasospasm, mean brain MMP-9 concentration on day D0 was seven fold higher than in asymptomatic patients. In symptomatic patients MMP-9 remained elevated over the entire period of measurements, while in asymptomatic patients MMP-9 was undetectable after 24 h. In one patient with no ischemic injury, MMP-9 increased, possibly in relation to bacterial meningitis.

Conclusions: We show for the first time that brain MMP-9 is increased in poor grade SAH patients and might be considered as a potential marker of delayed cerebral ischemia. Further studies are needed to confirm our preliminary results.